Sector News

After 2 years, Sanofi’s drug ingredients spinoff takes flight

May 7, 2022
Life sciences

It’s official: Two years and one pandemic after Sanofi unveiled plans to spin off its European drug ingredients business, EUROAPI has debuted on the Euronext exchange. Shares in the new active pharmaceutical ingredient (API) outfit rose more than 3% in early trading despite a wider market slump.

EUROAPI is touting its position as a “leading player” on the API scene. Its launch comes as COVID-19 and, more recently, the war in Ukraine expose gaps in the world’s pharmaceutical supply chain. Many of the ingredients the pharmaceutical industry relies on are made in countries like China and India.

EUROAPI is angling to become the “partner of choice for all pharmaceutical and biotech companies.” It’s previously said it believes it’s the world’s top manufacturer of small molecules and the second largest API maker by revenue.

The Sanofi spinoff boasts a portfolio of roughly 200 APIs, which it markets to more than 500 customers across 80-plus countries, EUROAPI noted in a release.

EUROAPI employs around 3,350 staffers and operates six “state-of-the-art” manufacturing and development centers in France, Germany, Hungary, Italy and the U.K.

“By operating as an independent company, EUROAPI will gain flexibility and growth opportunities to reinforce its status as partner of choice for all pharmaceutical and biotech companies,” Karl Rotthier, the company’s CEO, said in a statement.

Sanofi has retained a roughly 30% stake in EUROAPI.

The company aims to generate 1 euros billion in 2022 revenue, building on the 893 million euros it posted last year. Looking ahead, the API process development and manufacturing market, which was valued at 72 billion euros (about $76.1 billion) in 2019, is expected to grow by about 6% to 7% per year until 2024, EUROAPI said.

At the same time, the global contract manufacturing and development market is expected to grow by 7% to 8% annually over that same stretch.

As part of its stock listing announcement, EUROAPI flagged four milestones on its strategic road map to capture the API market.

The company aims to accelerate its work as a CDMO, develop its existing product portfolio, expand its technical platforms and presence in highly differentiated and complex APIs and ensure operational efficiencies, EUROAPI said.

Sanofi pulled back the curtain on its API spinoff in 2020 as CEO Paul Hudson embarked on a quest to trim 2 billion euros from Sanofi’s annual expenses by 2022.

After joining the French drug major in 2019, the CEO imposed a “play to win” strategy, part of which involved deprioritizing struggling disease areas to double down in growth fields.

By Fraiser Kansteiner

Source: fiercepharma.com

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”